Cradle-to-grave life cycle assessment of packaging material for a pharmaceutical company
- Authors: Sipuka, Siphokazi
- Date: 2018-04
- Subjects: Drugs -- Packaging , Drugs -- Packaging -- Quality control , Drugs -- Design
- Language: English
- Type: Master's theses , text
- Identifier: http://hdl.handle.net/10948/66533 , vital:75588
- Description: Due to anthropogenic activity as a result of the industrial revolution, the earth’s climate has changed drastically and key decision makers, including the public, have begun to recognize the need for action to be taken in order to curb global warming (Goodall, 2007). Businesses, policymakers and governments have been tasked with finding means and ways to reduce greenhouse gas (GHG) emissions. The need to better understand the activities that drive GHG emissions and how they can successfully be reduced has become strategic for various organisations (Business Gateway, 2012). The carbon footprint concept was born as a result of the need for a tool to estimate GHG emissions (Wiedmann and Minx, 2007). The primary objective of this research study was to determine the level of awareness of the environmental carbon footprint within the various functional units including procurement, planning, packaging, production, logistics, projects, quality and safety, health and environment of the packaging supply base. The aim was to also gain insight into whether the carbon footprint is taken into consideration during the packaging design stage, as well as to understand the level of carbon footprint quantification currently being conducted by the various functional units within packaging organisations. Pharmaceutical packaging represents a significant percentage of the carbon footprint emissions and is possibly the single largest contributor of carbon footprint emissions in various organisations’ value chain (Business Gateway, 2012). An empirical study was conducted using a questionnaire in a sample of fifty key strategic packaging suppliers who manufacture both locally and abroad. Data analysis was conducted in order to investigate the primary objectives of the research study. The key findings and recommendations to the organisations' management are presented in the study. , Thesis (MBA) -- Faculty of Business and Economic Sciences, Business School, 2018
- Full Text:
- Date Issued: 2018-04
Formulation and process optimisation of ethionamide 250 MGtablets using quality by design principles
- Authors: Isaacs, Nasreen
- Date: 2015
- Subjects: Pharmaceutical chemistry , Drugs -- Design , Pharmaceutical technology
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/3979 , vital:20497
- Description: The traditional approach of Quality by Testing (QbT) limits the assurance of product quality to in-process and post-production testing. To overcome these limitations, a more proactive and systematic means to product development and optimisation is required. Quality by Design (QbD) is an example of such an approach which focuses on understanding the product and its manufacturing process and emphasises that quality should be built into the product and not merely tested. The study aims to optimise ethionamide tablets, an immediate release oral solid dosage form using QbD.
- Full Text:
- Date Issued: 2015